Document text
Principal Investigator: EVAN J ANDERSON
Organization: EMORY UNIVERSITY
Fiscal Year: 2021
Award: $1,475,091
Funding agency: National Institute of Allergy and Infectious Diseases
Narrative
The Emory VTEU will participate and enroll children into “A Phase 2/3, Two-Part, Open-Label,
Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled
Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of
mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age
(KidCOVE)”.
1
Terms: <0-11 years old><12 year old><12 years of age><2019-nCoV vaccine><Age><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 vaccine><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccine><Child><Child Youth><Childhood><Children (0-21)><Clinical Trials><Dose><Effectiveness><Enrollment><Evaluation><Funding><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Phase><Placebos><Randomized><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><Safety><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Sham Treatment><Vaccines><age 12 years><ages><blind><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><enroll><fight against><mRNA-1273><mRNA1273><open label><open label study><pediatric><randomisation><randomization><randomly assigned><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><sham therapy><twelve year old><twelve years of age><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><youngster>